Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 6/20 | 0.51 |
| ▸ | FLT3 | P36888 | 8/20 | 0.50 |
| ▸ | CDK2 | P24941 | 3/20 | 0.50 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.50 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.50 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.47 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 2/20 | 0.46 |
| ▸ | JAK1 | P23458 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL954374 | 0.91 | JAK2 (0.49) | CSNK2A1FLT3CDK2CCNA2CCNA1 | |
| SCHEMBL952936 | 0.82 | FLT3 (0.72) | CSNK2A1FLT3CDK2CCNA2CCNA1 | |
| SCHEMBL952349 | 0.76 | CSNK2A1 (0.69) | CSNK2A1FLT3CDK2CCNA2CCNA1 | |
| SCHEMBL4007094 | 0.76 | FLT3 (0.72) | CSNK2A1FLT3CDK2CCNA2CCNA1 | |
| SCHEMBL4526067 | 0.75 | FLT3 (0.68) | CSNK2A1FLT3CDK2CCNA2CCNA1 | |
| SCHEMBL82695 | 0.73 | CSNK2A1 (0.52) | CSNK2A1FLT3CDK2CCNA2CCNA1 | |
| SCHEMBL954669 | 0.72 | FLT3 (0.78) | CSNK2A1FLT3CDK2CCNA2CCNA1 | |
| SCHEMBL28775976 | 0.71 | DYRK1A (0.66) | CSNK2A1FLT3CDK2CCNA2CCNA1 | |
| SCHEMBL4531693 | 0.70 | FLT3 (0.55) | CSNK2A1FLT3CDK2CCNA2CCNA1 | |
| SCHEMBL4510064 | 0.70 | EPHB3 (0.64) | CSNK2A1FLT3CDK2CCNA2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004000-A1 | Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors | SANOFI-AVENTIS (FR) | 2006-01-05 | — | — | US | claimed |
| US-7482342-B2 | Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors | SANOFI-AVENTIS (FR) | 2009-01-27 | — | — | US | disclosed |
| US-20060004000-A1 | Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors | SANOFI-AVENTIS (FR) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004000-A1 | Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors | CDK2, CDK1, CDK4 | CSNK2A1 62/4885FLT3 255/4885CDK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.